2012 Fiscal Year Final Research Report
Synergic anticancer effect of Itraconazole combination therapy onBevacizumab-resistant cancer cell
| Project/Area Number |
23791556
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Nagoya City University |
|---|
Principal Investigator |
HARA Masayasu 名古屋市立大学, 大学院・医学研究科, 助教 (80528860)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Keywords | 抗血管新生 / VEGF / Bevacizumab 耐性 |
|---|
| Research Abstract |
We clarified antiangiogenetic effect of Itraconazole, one of the antifungus drugs. This effect is based on the mechanism which is quite different from that of Bevacizumab. We also clarified it is based on direct anti-proliferation effect on endothelial cells not based on other angiogenetic cytokines. Our results showed that this Itraconazole’s effect is same as mTOR inhibitor, less toxicity than mTOR inhibitor and synergic effect with Bevacizumab on Bevacizumab resistant cancer cell.
|
